-
Canada to announce response to Trump's new tariffs
-
Six months into Iran war, Hormuz traffic way down, sailors stranded
-
Stocks stagger and oil rises as traders eye Iran threat, Nvidia results
-
Netanyahu got his Iran war, but maybe not his desired result
-
Families of detained Chinese Christians cling to faith in legal limbo
-
Hyundai reaches tentative deal with workers after strikes
-
Trump veers from boredom to denial after six months of Iran war
-
Once its saviour, US puts Kuwait in Iran's crosshairs
-
Cool Japan: Human fridge chills workers in extreme heat
-
Australia's top music charts ban AI songs
-
Tens of thousands flee fire near US city of Reno
-
How the French language contributed to the US-Canada trade war
-
Despair and anger erupt after deadly Guinea landfill collapse
-
Nevada sues US govt over cuts to Colorado River access
-
Tornado tears through French village, dozens injured
-
'Special' Chelsea forwards inspire Alonso's winning start
-
Federer looks forward to brief return to Arthur Ashe stadium
-
Alonso makes winning start with Chelsea as Rogers scores on debut
-
US removes Syria from state sponsor of terrorism list
-
Oil prices fall as Bessent outlines new steps to punish Iran
-
Facebook, TikTok promoted Colombian armed groups' content to recruit children: HRW
-
Saudi Arabia to invest $7 bn in theme parks near Paris
-
Palmeiras agree to sell Allan to Manchester City: source
-
British PM Burnham hits a chord on Kyiv visit
-
US vows 'economic asphyxiation' of Iran with new sanctions
-
Saudi Arabia to invest $7 bn in theme parks near Paris: French presidency
-
French tourist dies after getting stuck in scorching Death Valley
-
Vuelta stage three abandoned in dangerous weather conditions
-
US proposes expanding UN Sudan arms embargo to entire country
-
Banned Vondrousova appeals doping suspension to CAS
-
Ceasefire verification mission heads to east DR Congo
-
Ukraine's allies pledge to continue support despite Russian threats
-
Carse dropped from England squad after nightclub incident
-
France readies high school phone ban for next month
-
Empire State Building climbers kiss outside court after viral proposal
-
Trump says to double tariffs on Canada autos as trade fight heats up
-
French poll shows Le Pen's biggest challenger may be hard left's Melenchon
-
Noosha Aubel: Hur mycket administrativt misslyckande tål Potsdam till?
-
Noosha Aubel: Πόση διοικητική αποτυχία μπορεί να αντέξει ακόμα το Πότσδαμ?
-
WeGolden Receives Best Gold Trading Platform Asia 2026 Recognition from TrustFinance Awards
-
WeMasterTrade Receives Best Instant Prop APAC 2026 Recognition from TrustFinance Awards
-
BtcDana Wins “Best Customer Support Experience – CFD Broker 2026” at the TrustFinance Performance Awards
-
MH Markets Recognized as Most Transparent Broker at the TrustFinance Awards 2026
-
Belgian pie-thrower, scourge of celebrities, dies at 80
-
Stocks, oil slip ahead of US threat of economic war against Iran
-
Eto'o urges support for embattled FIFA president Infantino
-
Trump claims Iran 'collapsing' as US threatens 'economic D-Day'
-
India in driver's seat in second Sri Lanka Test
-
Noosha Aubel: Kolik administrativních selhání ještě Potsdam snese?
-
Noosha Aubel: Ile jeszcze nieudolności administracyjnej wytrzyma Poczdam?
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
F.Moura--PC